SI3041513T1 - Zwitterionski polimerni konjugati faktorja VIII - Google Patents

Zwitterionski polimerni konjugati faktorja VIII

Info

Publication number
SI3041513T1
SI3041513T1 SI201431684T SI201431684T SI3041513T1 SI 3041513 T1 SI3041513 T1 SI 3041513T1 SI 201431684 T SI201431684 T SI 201431684T SI 201431684 T SI201431684 T SI 201431684T SI 3041513 T1 SI3041513 T1 SI 3041513T1
Authority
SI
Slovenia
Prior art keywords
factor viii
polymer conjugates
zwitterionic polymer
zwitterionic
conjugates
Prior art date
Application number
SI201431684T
Other languages
English (en)
Slovenian (sl)
Inventor
Stephen A. Charles
D. Victor Perlroth
Li Song
Martin Linsell
Wayne To
Didier Benoit
James Aggen
Original Assignee
Kodiak Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodiak Sciences Inc. filed Critical Kodiak Sciences Inc.
Publication of SI3041513T1 publication Critical patent/SI3041513T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C08G65/33324—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group acyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Graft Or Block Polymers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201431684T 2013-09-08 2014-09-08 Zwitterionski polimerni konjugati faktorja VIII SI3041513T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875099P 2013-09-08 2013-09-08
EP14841835.3A EP3041513B1 (en) 2013-09-08 2014-09-08 Factor viii zwitterionic polymer conjugates
PCT/US2014/054622 WO2015035342A2 (en) 2013-09-08 2014-09-08 Factor viii zwitterionic polymer conjugates

Publications (1)

Publication Number Publication Date
SI3041513T1 true SI3041513T1 (sl) 2020-11-30

Family

ID=52629093

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431684T SI3041513T1 (sl) 2013-09-08 2014-09-08 Zwitterionski polimerni konjugati faktorja VIII

Country Status (11)

Country Link
US (3) US10702608B2 (enExample)
EP (2) EP3760639B1 (enExample)
JP (5) JP6463361B2 (enExample)
DK (1) DK3041513T3 (enExample)
ES (1) ES2819217T3 (enExample)
HU (1) HUE052447T2 (enExample)
LT (1) LT3041513T (enExample)
PL (1) PL3041513T3 (enExample)
PT (1) PT3041513T (enExample)
SI (1) SI3041513T1 (enExample)
WO (1) WO2015035342A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20240043795A (ko) 2021-10-19 2024-04-03 주식회사 히타치하이테크 하전 입자선 장치
WO2025184423A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Cell-surface-targeting-domain-polymer-payload conjugate
WO2025190493A1 (de) 2024-03-15 2025-09-18 Alexander Wolf Pyrolyseanlage zum chargenweisen herstellen von pflanzenkohle durch pyrolyse von biomasse sowie verfahren

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5296363A (en) 1976-02-06 1977-08-12 Takamatsu Electric Works Ltd Device for supplementing gas in gas sealed distributing device
JPS5472168A (en) 1977-11-18 1979-06-09 Tiger Vacuum Bottle Ind Electric cooking implement
JPS5846044B2 (ja) 1979-04-14 1983-10-14 日本金属株式会社 圧粉鉄心
JPS5745009U (enExample) 1980-08-26 1982-03-12
JPS6337605Y2 (enExample) 1980-09-19 1988-10-05
JPS5846044U (ja) 1981-09-22 1983-03-28 桜井　幸雄 掘りごたつ
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE190988T1 (de) 1991-07-05 2000-04-15 Biocompatibles Ltd Polymere oberflächenbeschichtungszusammensetzungen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2133072C (en) 1992-03-27 2005-02-22 Anthony Evan Shakspeare Packages for infusible substances
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE316981T1 (de) 1992-10-02 2006-02-15 Inst Genetics Llc Zusammensetzung, welche den koagulationsfaktor viii beinhalted; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9301702D0 (en) 1993-01-28 1993-03-17 Biocompatibles Ltd New materials
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9324033D0 (en) 1993-11-23 1994-01-12 Biocompatibles Ltd Ethylenically unsaturated compounds
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6541580B1 (en) 1995-03-31 2003-04-01 Carnegie Mellon University Atom or group transfer radical polymerization
US5763548A (en) 1995-03-31 1998-06-09 Carnegie-Mellon University (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
GB9521234D0 (en) 1995-10-16 1995-12-20 Biocompatibles Ltd Synthesis of polymerisable phospho diesters
WO1997014702A1 (en) 1995-10-16 1997-04-24 Biocompatibles Limited Oxidation of phosphorus compounds
US5807937A (en) 1995-11-15 1998-09-15 Carnegie Mellon University Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties
US5663425A (en) 1996-01-26 1997-09-02 Lignotech Usa, Inc. Production of acid soluble humates
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5789487A (en) 1996-07-10 1998-08-04 Carnegie-Mellon University Preparation of novel homo- and copolymers using atom transfer radical polymerization
JPH10139832A (ja) 1996-11-08 1998-05-26 Nof Corp 共重合体およびグルコースセンサー
US7125938B2 (en) 1997-03-11 2006-10-24 Carnegie Mellon University Atom or group transfer radical polymerization
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
JP3052923B2 (ja) 1997-05-30 2000-06-19 日本油脂株式会社 （メタ）アクリレート誘導体の製造方法
CN1295680A (zh) 1998-01-30 2001-05-16 第一化学公司 含有马来酰亚胺的光致聚合组合物及其使用方法
JP4162284B2 (ja) 1998-02-04 2008-10-08 日油株式会社 洗浄剤組成物
US6121371A (en) 1998-07-31 2000-09-19 Carnegie Mellon University Application of atom transfer radical polymerization to water-borne polymerization systems
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
JP4145403B2 (ja) 1998-09-29 2008-09-03 日油株式会社 免疫学的活性物質測定用高分子／酵素結合体
AU4195100A (en) 1999-04-05 2000-10-23 Research Foundation Of State University Of New York, The Graft, graft-block, block-graft, and star-shaped copolymers and methods of making them
FR2794459B1 (fr) 1999-05-19 2004-09-03 Atofina Polyalcoxyamines issues de nitroxydes beta-substitues
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
US7049373B2 (en) 1999-08-06 2006-05-23 Carnegie Mellon University Process for preparation of graft polymers
JP4883515B2 (ja) 1999-09-08 2012-02-22 ポリセリックス リミテッド 均一分子量ポリマー
US6348554B1 (en) 1999-11-30 2002-02-19 Rohmax Additives Gmbh Method for preparation of a liquid polymer composition and use of this composition
GB9928956D0 (en) 1999-12-07 2000-02-02 Malik Navid Internally supported biomimetic coating systems
EP1801129A3 (en) 2000-10-06 2008-02-20 Carnegie-Mellon University Polymerization process for ionic monomers
WO2002028912A2 (en) 2000-10-06 2002-04-11 Carnegie Mellon University Preparation of nanocomposite structures by controlled polymerization
AU2001292092A1 (en) 2000-10-06 2002-04-15 Biocompatibles Uk Limited Zwitterionic polymers
WO2002028914A2 (en) 2000-10-06 2002-04-11 Carnegie Mellon University A catalyst system for controlled polymerization
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE60236642D1 (de) 2001-04-06 2010-07-22 Univ Carnegie Mellon Verfahren zur herstellung von nanostrukturierten materialien
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
AU2002361223A1 (en) 2001-08-27 2003-03-18 Zeptosens Ag Bioanalytical recognition surface with optimised recognition element density
JP2003064132A (ja) 2001-08-28 2003-03-05 Nof Corp 重合体、製造方法および乳化・分散剤
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7064166B2 (en) 2001-10-12 2006-06-20 Carnegie Mellon University Process for monomer sequence control in polymerizations
US6759491B2 (en) 2001-10-12 2004-07-06 Carnegie Mellon University Simultaneous reverse and normal initiation of ATRP
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
WO2003074090A2 (en) 2002-03-07 2003-09-12 Biocompatibles Uk Limited Compositions of polymers
AU2003214387A1 (en) 2002-03-07 2003-09-16 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7196142B2 (en) 2002-04-04 2007-03-27 The University Of Akron Polyisobutylene-based block anionomers and cationomers and synthesis thereof
JP4248189B2 (ja) 2002-04-09 2009-04-02 株式会社資生堂 ホスホリルコリン基含有多糖類及びその製造方法
AU2003241531A1 (en) 2002-05-21 2003-12-12 Emory University Multivalent polymers with chain-terminating binding groups
EP1534764B1 (en) 2002-08-09 2014-07-16 Carnegie Mellon University Polymers, supersoft elastomers and methods for preparing the same
US20060165804A1 (en) 2002-09-25 2006-07-27 Lewis Andrew L Polymer compositions for administration to animals
US7737237B2 (en) 2002-11-07 2010-06-15 Phodia Chimie Controlled structure copolymer comprising an amphoteric or zwitterionic part
US20070111279A1 (en) 2002-11-13 2007-05-17 Procell, Inc. Production of recombinant therapeutic bioscavengers against chemical and biological agents
GB0301014D0 (en) 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US20060167230A1 (en) 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
US7820753B2 (en) 2003-02-05 2010-10-26 Biocompatibles Uk Limited Block copolymers
ZA200506159B (en) 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
CN101514223B (zh) 2003-04-11 2017-03-01 安特里阿比奥有限公司 位点特异性蛋白质偶联物的制备方法
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
CN1208358C (zh) 2003-07-31 2005-06-29 上海交通大学 含多羟基官能团多臂星状超支化聚合物刷及其制备方法
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
PL1660057T3 (pl) 2003-08-27 2012-10-31 Ophthotech Corp Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
BRPI0406606A (pt) 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
RS53279B (sr) 2003-12-16 2014-08-29 Nektar Therapeutics Monodisperzne smeše pegilisanog naloksola
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
KR100593443B1 (ko) 2004-02-11 2006-06-28 삼성전자주식회사 트랜지스터들 및 그 제조방법들
JP4727938B2 (ja) 2004-02-24 2011-07-20 泰彦 岩崎 リビングラジカル重合開始基を持つポリリン酸の製造方法および用途
ATE507240T1 (de) 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP4727941B2 (ja) 2004-03-12 2011-07-20 泰彦 岩崎 生分解性重合体の製造方法および用途
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US20090249503A1 (en) 2004-12-06 2009-10-01 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
WO2006066171A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
EP1672192B1 (en) 2004-12-18 2007-08-08 Haldor Topsoe A/S Method for controlling injection of reducing agent in exhaust gas from a combustion engine
TW200714290A (en) 2005-03-08 2007-04-16 Pharmacia & Upjohn Co Llc Anti-M-CSF antibody compositions having reduced levels of endotoxin
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
JP5541861B2 (ja) 2005-04-29 2014-07-09 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 超分岐ポリマーおよびそれらの適用
US20070005130A1 (en) 2005-06-29 2007-01-04 Thierry Glauser Biodegradable polymer for coating
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1943278B1 (en) 2005-08-26 2010-10-06 Carnegie Mellon University Polymerization process with catalyst reactivation
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
US7906134B2 (en) 2005-12-21 2011-03-15 Abbott Laboratories Room temperature-curable polymers
DE102006009004A1 (de) 2006-02-23 2007-09-06 Sustech Gmbh & Co. Kg Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung
EP1988910B1 (en) 2006-02-28 2017-12-06 Kodiak Sciences Inc. Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
JP2007263935A (ja) 2006-03-30 2007-10-11 Canon Inc 磁性マーカー及びその製造方法
EP2010584A4 (en) 2006-04-14 2010-07-21 Interface Biologics Inc GRAFT POLYMERS AND USES THEREOF
JP5030036B2 (ja) 2006-05-23 2012-09-19 一彦 石原 生体成分固定化ポリマー組成物および三次元架橋体
CN101511892B (zh) 2006-06-29 2012-02-29 英维特罗根戴内尔公司 含有多嵌段聚合物的颗粒
US20080008736A1 (en) 2006-07-06 2008-01-10 Thierry Glauser Random copolymers of methacrylates and acrylates
WO2008006912A2 (en) 2006-07-14 2008-01-17 Biocompatibles Uk Limited Polymer
KR100808116B1 (ko) 2006-08-22 2008-03-03 전남대학교산학협력단 미생물 점착 방지용 공중합체 수지 코팅재
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
JP5111016B2 (ja) 2006-11-01 2012-12-26 三井化学株式会社 表面親水性ポリオレフィン成形体およびその製造方法
WO2008064058A2 (en) 2006-11-21 2008-05-29 Abbott Laboratories Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US7651527B2 (en) 2006-12-15 2010-01-26 Medtronic Vascular, Inc. Bioresorbable stent
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
TW200838875A (en) 2007-02-01 2008-10-01 Genentech Inc Combination therapy with angiogenesis inhibitors
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
WO2008112257A1 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-antihistamine conjugates
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
CN101053681B (zh) 2007-04-10 2010-05-19 天津大学 用于血管栓塞材料的温敏性MPC-b-NIPAM二嵌段星型共聚物及制备方法和应用
BRPI0810374A2 (pt) 2007-04-17 2014-10-29 Imclone Llc Inibidores específicos do pdgfrbeta
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2684153A1 (en) 2007-05-14 2008-11-27 Tyco Healthcare Group Lp Furanone copolymers
JP5019524B2 (ja) 2007-06-01 2012-09-05 国立大学法人 東京大学 新規ポリ（メタ）アクリレート共重合体ならびに小胞体及びゴルジ体への送達方法
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
JP2009042617A (ja) 2007-08-10 2009-02-26 Canon Inc 静電荷像現像用トナー及びその製造方法
US7943370B2 (en) 2007-08-23 2011-05-17 Canon Kabushiki Kaisha Structure, target substance detection element and target substance detection kit
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
JP2009114283A (ja) 2007-11-05 2009-05-28 Asahi Kasei Chemicals Corp 吸引用シートおよびそれを用いた装置
JPWO2009066746A1 (ja) 2007-11-22 2011-04-07 国立大学法人 東京大学 組織癒着防止材および関節拘縮防止材
MX2010007767A (es) 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
JP5344420B2 (ja) 2008-05-15 2013-11-20 独立行政法人国立循環器病研究センター 遺伝子導入剤及びその製造方法並びに核酸複合体
EP2282720B1 (en) 2008-05-15 2013-09-11 Biocompatibles Uk Ltd. Intracellular antibody delivery
WO2009158461A1 (en) 2008-06-25 2009-12-30 Boston Scientific Scimed, Inc. Medical copolymers
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP2010117189A (ja) 2008-11-12 2010-05-27 Sumitomo Bakelite Co Ltd 生理活性物質固定化用基板
CA2745307A1 (en) 2008-12-12 2010-06-17 University Of Massachusetts Polyesters with grafted zwitterions
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
WO2010075423A2 (en) 2008-12-23 2010-07-01 The Regents Of The University Of Michigan Dendrimer based modular platforms
MX2011009810A (es) 2009-03-27 2011-09-30 Zymogenetics Inc Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CN101575402B (zh) 2009-05-31 2012-06-27 中国科学院化学研究所 一种多臂星型聚合物及其制备方法
EP2260873B1 (en) 2009-06-08 2019-07-24 Biocompatibles UK Limited Pcylation of proteins
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
CN102025901A (zh) 2009-09-23 2011-04-20 国基电子（上海）有限公司 相机模组及其检测方法
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
US20120282211A1 (en) 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
AR078377A1 (es) 2009-12-11 2011-11-02 Genentech Inc Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP2536754A1 (en) 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
KR20200067958A (ko) 2010-04-15 2020-06-12 코디악 사이언시스 인코포레이티드 고분자량 쌍성이온-함유 중합체
JP2012025820A (ja) 2010-07-21 2012-02-09 Kansai Paint Co Ltd 親水化処理剤組成物
WO2012099376A2 (ko) 2011-01-17 2012-07-26 주식회사 엘지화학 신규한 화합물 및 이를 포함하는 유기 발광 소자
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
WO2013059137A1 (en) * 2011-10-17 2013-04-25 Oligasis High molecular weight zwitterion-containing polymers
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2834271B1 (en) 2012-04-03 2019-01-16 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
JP6234064B2 (ja) 2012-05-23 2017-11-22 キヤノン株式会社 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法
JP5846044B2 (ja) 2012-05-23 2016-01-20 日油株式会社 （メタ）アクリル酸誘導体の製造方法
WO2014060401A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
CN103193819A (zh) 2013-03-13 2013-07-10 苏州蔻美新材料有限公司 一锅法合成mpc的方法
HUE060464T2 (hu) 2013-03-13 2023-03-28 Genzyme Corp PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására
SG11201509982UA (enExample) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
CN103421039B (zh) 2013-09-03 2015-12-23 重庆工商大学 2-甲基丙烯酰氧基乙基磷酰胆碱的合成方法
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240209076A1 (en) 2020-05-08 2024-06-27 Kodiak Sciences Inc. Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof
EP4323399A4 (en) 2021-04-14 2025-04-09 Kodiak Sciences Inc. Methods of treating an eye disorder
IL314472A (en) 2022-02-10 2024-09-01 Kodiak Sciences Inc Product purification methods

Also Published As

Publication number Publication date
JP7232796B2 (ja) 2023-03-03
JP2020183404A (ja) 2020-11-12
PT3041513T (pt) 2020-09-07
HUE052447T2 (hu) 2021-04-28
WO2015035342A2 (en) 2015-03-12
EP3041513A4 (en) 2017-04-12
EP3760639B1 (en) 2025-10-22
LT3041513T (lt) 2020-11-25
WO2015035342A3 (en) 2015-04-30
ES2819217T3 (es) 2021-04-15
JP2023029851A (ja) 2023-03-07
EP3760639A1 (en) 2021-01-06
US20200261590A1 (en) 2020-08-20
PL3041513T3 (pl) 2021-01-25
US12214044B2 (en) 2025-02-04
US11590235B2 (en) 2023-02-28
JP2025165944A (ja) 2025-11-05
JP6463361B2 (ja) 2019-01-30
US20160199501A1 (en) 2016-07-14
JP6732056B2 (ja) 2020-07-29
US20230173081A1 (en) 2023-06-08
EP3041513B1 (en) 2020-08-05
JP2019081765A (ja) 2019-05-30
DK3041513T3 (da) 2020-10-26
JP7767260B2 (ja) 2025-11-11
US10702608B2 (en) 2020-07-07
EP3041513A2 (en) 2016-07-13
JP2016530302A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
FR23C1020I2 (fr) Conjugues pyrrolobenzodiazepine-anticorps
DK3460054T3 (da) Histidyl-tRNA-syntetase-Fc-konjugater
EP2975043A4 (en) Olefin-based polymer
DK2906251T3 (da) Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
BR112015008232A2 (pt) conjugados pirrolbenzodiazepina-anticorpo
PL3088419T3 (pl) Koniugat lek-przeciwciało anty-trop2
BR112016015105A8 (pt) conjugados var2csa-droga
DK3054991T3 (da) Protein-polymer-lægemiddelkonjugater
LT3003386T (lt) Antikūno-vaisto konjugatai
DK2984138T3 (da) Polymersammensætning
EP2987125A4 (en) LINKED ADVERTISING CONTENT
DK3054992T3 (da) Protein-polymer-lægemiddelkonjugater
SI3041513T1 (sl) Zwitterionski polimerni konjugati faktorja VIII
EP2970645A4 (en) HINGE POLYMER
EP3071183C0 (en) CAVITATION-INDUCING POLYMERIC NANOPARTICLES
DK2917244T3 (da) Aprotinin-afledte polypeptid-antistofkonjugater
CL2016001382A1 (es) Estabilidad de gel mejorada
UA31799S (uk) Упаковка
DK3080385T3 (da) Forbedret lukkeapparat
DE102014109920A8 (de) Drehmelder
EP2894773A4 (en) COORDINATE CONVERTERS
GB201308738D0 (en) Novel polymer conjugates
EP2954064C0 (en) CYCLODEXTRIN GLUCANOTRANSFERASE
LT2948504T (lt) Polimerinės medžiagos
TH1401006664A (th) โพลีเมอร์ปลายคาร์บินอลที่บรรจุอัลลิลเอมีน